Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about atopic dermatitis

Recent news which mentions atopic dermatitis

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Tickers JNJ NEWS SWAV
Tags Stories That Matter Large Cap JNJ
From Benzinga
Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis
Tickers LLY
Tags General atopic dermatitis Briefs
From Benzinga
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
Tickers VYNE
Tags VYNE Penny Stocks Trading Ideas
From Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
Tickers REGN SNY
Tags SNY atopic dermatitis General
From Benzinga
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
Tickers ASLN
Tags Trading Ideas Penny Stocks Benzinga
From Benzinga
FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older
Tickers ABBV
Tags atopic dermatitis General Biotech
From Benzinga
EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa
Tickers HOTH
Tags Biotech Benzinga Exclusives
From Benzinga
Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint
Tickers CNTB
Tags General atopic dermatitis Movers
From Benzinga
AbbVie Presents New Upadacitinib Data In Atopic Dermatitis
Tickers ABBV
Tags Biotech Briefs Benzinga
From Benzinga
Pfizers' JAK Inhibitor Approved In Japan For Atopic Dermatitis
Tickers PFE
Tags PFE Health Care News
From Benzinga
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
Tickers ASLN
Tags Market News News ASLN
From Benzinga
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
Tickers INCY
Tags General atopic dermatitis Movers
From Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Tickers PFE REGN SNY
Tags Phase 3 Trial PFE Benzinga
From Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
Tickers REGN SNY
Tags News Health Care Market News
From Benzinga
Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials
Tickers LLY
Tags Market News Health Care Phase 3 Trial
From Benzinga
VYNE Therapeutics Stock Drops On Potential Sale Of Topical Minocycline Franchise
Tickers VYNE
Tags inflammatory diseases Benzinga Biotech
From Benzinga
FDA Will Not Meet Goal Dates For Pfizer's Xeljanz, Abrocitinib Applications
Tickers PFE
Tags Market News News Health Care
From Benzinga
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
Tickers ABBV INCY LLY
Tags Benzinga Briefs LLY
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.